Latest news with #HCAb
Business Wire
17-06-2025
- Business
- Business Wire
Biocytogen Responds to Harbour BioMed's Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
BEIJING--(BUSINESS WIRE)--In response to Harbour BioMed's recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen's proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute. 120 vs. 9 – A Significant Technical Divide of RenNano® Platform; Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights The RenNano® platform employs a large-fragment knock-in strategy that incorporates over 120 human V genes in situ, enabling a complete and functional human heavy chain antibody repertoire. In stark contrast, Harbour BioMed's HCAb platform introduces only 9 V genes through a small-fragment transgenic approach. This key difference reflects not only divergent technical strategies but also the depth, innovation, and translational potential of Biocytogen's antibody discovery platforms. The decision referenced in Harbour BioMed's PR involves a procedural ruling on jurisdiction only and does not address the substance of the patent infringement case. Furthermore, the CNIPA's affirmation of patent validity is a routine administrative process that does not imply infringement. The underlying lawsuit has not yet entered the trial phase. Biocytogen is currently evaluating all legal options and will resolutely defend its IP rights and scientific reputation. The RenNano® platform has been fully validated and is supported by a robust portfolio of domestic and international patents, clearly documenting its originality and independence. We remain confident in: The technical integrity and legal foundation of the RenNano® platform; The non-infringement of any third-party IP; Our continued leadership in antibody discovery and therapeutic innovation. According to public records, the Chinese patent related to Harbour BioMed's HCAb platform is set to expire on July 22, 2025, further underscoring the short-sighted nature of any speculative claims. Regardless, Biocytogen will continue to uphold its rights, ensure business continuity, and deliver transformative technologies for global partners and patients. Any misleading allegations or speculative narratives will not deter our team from advancing the RenMice® platform series with world-class innovation and delivering on our mission to accelerate therapeutic discovery. Key Technical Differences Between Biocytogen's RenNano® Platform and Harbour BioMed's HCAb Platform Biocytogen RenNano® Platform: Uses large-fragment knock-in technology to replace mouse genes with over 120 human V genes in situ, resulting in a full and functional human heavy chain variable region genomic repertoire. Harbour BioMed HCAb Platform: Introduces only 9 V genes using small-fragment transgenic approaches. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
Malaysian Reserve
16-06-2025
- Business
- Malaysian Reserve
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments in its intellectual property (IP) protection efforts. Following an invalidation request filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ('Biocytogen') against Harbour BioMed's patent entitled 'Binding Molecule' (Patent Application No. CN201210057668.0, the 'HCAb Patent'), the China National Intellectual Property Administration ('CNIPA') issued a final decision on June 5, 2025, upholding the patent under Articles 22.3, 26.3, 26.4, and 33 of the Patent Law of the People's Republic of China. The HCAb patent covers a method for producing fully human heavy chain-only antibodies (HCAbs) utilizing transgenic animals. On September 27, 2024, Harbour BioMed filed a patent infringement lawsuit with the Shanghai Intellectual Property Court against Biocytogen, alleging that its RenNano platform infringes Harbour BioMed's HCAb Patent. Biocytogen subsequently challenged the court's jurisdiction, first through an objection submitted to the Shanghai Intellectual Property Court on November 8, 2024, and later through an appeal to the Supreme People's Court of the People's Republic of China on March 14, 2025. On May 27, 2025, the Supreme People's Court of the People's Republic of China issued a final ruling, dismissing the appeal and affirming the jurisdiction of the Shanghai Intellectual Property Court over the infringement lawsuit. This case has now advanced to the next stage of trial. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: 'CNIPA's decision affirms the rightful protections of the pioneering innovation and core value of Harbour BioMed's intellectual property. We have established a global patent portfolio across key markets, providing robust protection for R&D investments and proprietary innovations enabled by our Harbour Mice® platform and associated technologies. Moving forward, we will continue to leverage our patented HCAb technology to accelerate the development of transformative therapies in collaboration with global partners, ultimately bringing meaningful benefits to patients worldwide.' About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit
Yahoo
16-06-2025
- Business
- Yahoo
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments in its intellectual property (IP) protection efforts. Following an invalidation request filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") against Harbour BioMed's patent entitled "Binding Molecule" (Patent Application No. CN201210057668.0, the "HCAb Patent"), the China National Intellectual Property Administration ("CNIPA") issued a final decision on June 5, 2025, upholding the patent under Articles 22.3, 26.3, 26.4, and 33 of the Patent Law of the People's Republic of China. The HCAb patent covers a method for producing fully human heavy chain-only antibodies (HCAbs) utilizing transgenic animals. On September 27, 2024, Harbour BioMed filed a patent infringement lawsuit with the Shanghai Intellectual Property Court against Biocytogen, alleging that its RenNano platform infringes Harbour BioMed's HCAb Patent. Biocytogen subsequently challenged the court's jurisdiction, first through an objection submitted to the Shanghai Intellectual Property Court on November 8, 2024, and later through an appeal to the Supreme People's Court of the People's Republic of China on March 14, 2025. On May 27, 2025, the Supreme People's Court of the People's Republic of China issued a final ruling, dismissing the appeal and affirming the jurisdiction of the Shanghai Intellectual Property Court over the infringement lawsuit. This case has now advanced to the next stage of trial. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: "CNIPA's decision affirms the rightful protections of the pioneering innovation and core value of Harbour BioMed's intellectual property. We have established a global patent portfolio across key markets, providing robust protection for R&D investments and proprietary innovations enabled by our Harbour Mice® platform and associated technologies. Moving forward, we will continue to leverage our patented HCAb technology to accelerate the development of transformative therapies in collaboration with global partners, ultimately bringing meaningful benefits to patients worldwide." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit View original content to download multimedia: SOURCE Harbour BioMed
Associated Press
07-03-2025
- Business
- Associated Press
Nona Biosciences Integrates Cutting-Edge AI Technology to Enhance Its Fully Human Antibody Platform, Accelerating Antibody Discovery Across Key Therapeutic Areas
CAMBRIDGE, Mass., March 7, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from 'Idea to IND' (I to ITM), today announced to unveil its innovative AI-assisted drug discovery engine, Hu-mAtrIxTM. This new platform, powered by advanced artificial intelligence, integrates seamlessly with the company's proprietary Harbour Mice® technology platform, aiming to accelerate antibody discovery across multiple key therapeutic areas, including neurodegenerative and metabolic diseases, and more. Nona's cutting-edge technology platform enables a fully integrated antibody discovery from protein design and single cell-based antibody screening to next-generation sequencing, antibody modeling and engineering. The Hu-mAtrIxTM platform is designed to significantly shorten discovery timelines, increase efficiency, and improve the overall success rate of antibody drug development by introducing a creative paradigm of antibody discovery empowered by AI and automation technologies. Hu-mAtrIxTM offers integrated solutions to identify the best antibodies with high efficiency. It allows the exploration of large libraries of human antibody sequences to identify the best sequence with the desired target specificity and binding affinity. Furthermore, it can predict the key antibody properties such as stability, manufacturability and immunogenicity, mitigating development risks in the early stages of discovery. In addition, Nona Biosciences is developing a new AI model to expand its core technology platform HCAb PlusTM. The new model leverages the unique capabilities of its HCAb Harbour Mice®, the industry's leading fully human heavy-chain-only transgenic mouse platform, and the proprietary HCAb dataset, to push the boundaries of antibody discovery, enabling the identification of rare, highly specific antibodies with greater precision and efficiency. 'We are excited to introduce the Hu-mAtrIxTM platform, an assistant tool to complement and enhance our existing antibody discovery solutions,' said Dr. Jingsong Wang, Chairman of Nona Biosciences. 'By combining our proprietary Harbour Mice® with the power of AI, we are addressing key challenges in drug discovery—reducing time-to-market, increasing the likelihood of successful candidates, and providing our partners with more targeted therapeutic options.' About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing a total solution from 'Idea to IND' (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:
